

**Biotechnology Fund**  
**SCHEDULE OF INVESTMENTS (Unaudited)**

June 30, 2024

	Shares	Value
<b>COMMON STOCKS<sup>†</sup> - 100.2%</b>		
<b>Biotechnology - 76.0%</b>		
Amgen, Inc.	21,642	\$ 6,762,043
Gilead Sciences, Inc.	70,331	4,825,410
Regeneron Pharmaceuticals, Inc.*	4,360	4,582,491
Vertex Pharmaceuticals, Inc.*	9,350	4,382,532
Alnylam Pharmaceuticals, Inc.*	14,179	3,445,497
Corteva, Inc.	58,795	3,171,402
Biogen, Inc.*	12,559	2,911,427
Moderna, Inc.*	24,446	2,902,962
Sarepta Therapeutics, Inc.*	13,412	2,119,096
Illumina, Inc.*	19,243	2,008,584
United Therapeutics Corp.*	6,215	1,979,788
BioMarin Pharmaceutical, Inc.*	24,030	1,978,390
Royalty Pharma plc — Class A	69,616	1,835,774
Insmed, Inc.*	25,565	1,712,855
Incyte Corp.*	27,942	1,693,844
Argenx SE ADR*	3,465	1,490,089
Legend Biotech Corp. ADR*	33,038	1,463,253
Ionis Pharmaceuticals, Inc.*	28,433	1,355,117
Halozyne Therapeutics, Inc.*	25,757	1,348,637
Intra-Cellular Therapies, Inc.*	19,307	1,322,336
Exelixis, Inc.*	57,665	1,295,733
Cytokinetics, Inc.*	23,294	1,262,069
REVOLUTION Medicines, Inc.*	31,620	1,227,172
Viking Therapeutics, Inc.*	22,516	1,193,573
Roivant Sciences Ltd.*	107,377	1,134,975
CRISPR Therapeutics AG*	20,853	1,126,271
Blueprint Medicines Corp.*	9,286	1,000,845
BioNTech SE ADR*	11,983	962,954
Axsome Therapeutics, Inc.*	11,908	958,594
Apellis Pharmaceuticals, Inc.*	23,678	908,288
Guardant Health, Inc.*	31,279	903,338
Crinetics Pharmaceuticals, Inc.*	20,096	900,100
Arrowhead Pharmaceuticals, Inc.*	34,574	898,578
Cerevel Therapeutics Holdings, Inc.*	21,727	888,417
Bridgebio Pharma, Inc.*	34,989	886,271
Ultragenyx Pharmaceutical, Inc.*	21,535	885,088
Amicus Therapeutics, Inc.*	83,358	826,911
TG Therapeutics, Inc.*	46,215	822,165
Prothena Corporation plc*	38,699	798,747
ACADIA Pharmaceuticals, Inc.*	45,448	738,530
Krystal Biotech, Inc.*	3,945	724,460
Iovance Biotherapeutics, Inc.*	89,606	718,640
Ardelyx, Inc.*	95,395	706,877
Intellia Therapeutics, Inc.*	29,606	662,582
Immunovant, Inc.*	25,064	661,690
PTC Therapeutics, Inc.*	21,151	646,798
Beam Therapeutics, Inc.*	26,919	630,712
Novavax, Inc.*	48,422	613,023
Nuvalent, Inc. — Class A*	8,070	612,190
SpringWorks Therapeutics, Inc.*	16,194	610,028
Dynavax Technologies Corp.*	52,921	594,303
Akero Therapeutics, Inc.*	25,245	592,248
Recursion Pharmaceuticals, Inc. — Class A*	74,126	555,945
Sage Therapeutics, Inc.*	32,164	349,301
GRAIL, Inc.*, <sup>1</sup>	3,199	49,166
<b>Total Biotechnology</b>		<b>81,638,109</b>
<b>Pharmaceuticals - 19.1%</b>		
AbbVie, Inc.	52,186	8,950,943
AstraZeneca plc ADR	36,119	2,816,921
Neurocrine Biosciences, Inc.*	13,507	1,859,509
Viatris, Inc.	171,258	1,820,472
Alkermes plc*	57,132	1,376,881
Jazz Pharmaceuticals plc*	11,663	1,244,792
Vaxcyte, Inc.*	16,322	1,232,474
Madrigal Pharmaceuticals, Inc.*	2,324	651,092
Ironwood Pharmaceuticals, Inc. — Class A*	76,610	499,497
<b>Total Pharmaceuticals</b>		<b>20,452,581</b>
<b>Healthcare-Products - 3.8%</b>		
Natera, Inc.*	16,365	1,772,166
Exact Sciences Corp.*	33,635	1,421,079
Twist Bioscience Corp.*	15,458	761,770
Pacific Biosciences of California, Inc.*, <sup>1</sup>	103,284	141,499
<b>Total Healthcare-Products</b>		<b>4,096,514</b>
<b>Healthcare-Services - 1.3%</b>		
Medpace Holdings, Inc.*	3,348	1,378,874
<b>Total Common Stocks</b>		<b>107,566,078</b>
(Cost \$55,989,203)		
	<b>Face Amount</b>	
<b>REPURCHASE AGREEMENTS<sup>††,2</sup> - 0.8%</b>		
J.P. Morgan Securities LLC issued 06/28/24 at 5.32% due 07/01/24	\$ 459,377	459,377
BofA Securities, Inc. issued 06/28/24 at 5.30% due 07/01/24	362,164	362,164
<b>Total Repurchase Agreements</b>		<b>821,541</b>
(Cost \$821,541)		
	<b>Shares</b>	
<b>SECURITIES LENDING COLLATERAL<sup>†,3</sup> - 0.1%</b>		
<b>Money Market Fund<sup>***</sup></b>		
First American Government Obligations Fund - Class X, 5.23% <sup>4</sup>	155,023	155,023

<b>Total Securities Lending Collateral</b>		
(Cost \$155,023)		155,023
<b>Total Investments - 101.1%</b>		
(Cost \$56,965,767)	\$	108,542,642
<b>Other Assets &amp; Liabilities, net - (1.1)%</b>		(1,152,914)
<b>Total Net Assets - 100.0%</b>	\$	107,389,728

**Biotechnology Fund**  
**SCHEDULE OF INVESTMENTS (Unaudited)**

June 30, 2024

- 
- \* Non-income producing security.
  - \*\*\* A copy of each underlying unaffiliated fund's statements is available at the SEC's website at [www.sec.gov](http://www.sec.gov).
  - † Value determined based on Level 1 inputs.
  - †† Value determined based on Level 2 inputs.
  - 1 All or a portion of this security is on loan at June 30, 2024.
  - 2 Repurchase Agreements.
  - 3 Securities lending collateral.
  - 4 Rate indicated is the 7-day yield as of June 30, 2024.

ADR — American Depositary Receipt  
plc — Public Limited Company